Quarterly report pursuant to Section 13 or 15(d)

Term Debt (Details Narrative)

Term Debt (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2020
Dec. 13, 2019
Term debt $ 8,000 $ 8,000  
Matures date   Jun. 01, 2024  
Debt issuance costs 50 $ 50  
Amortized to interest expense $ 2 $ 21  
Term debt, description   (i) one-half of one percent (0.50%) above the Prime Rate and (ii) five and one-half percent (5.50%). At June 30, 2020, the interest rate was 5.50%. The Term Debt is collateralized by substantially all assets of the Company. Additionally, the Company has pledged 65% of the outstanding capital stock in the Company's foreign subsidiary, Motus GI Medical Technologies, Ltd., to collateralize the Term Debt.  
Interest, description   Interest payments have commenced on January 1, 2020, following each month until the maturity date. Principal payments will commence July 1, 2022 and continuing for 24 consecutive months thereafter. The Company may prepay all, but not less than all, of the outstanding principal balance of the Term Debt subject to prepayment premium of $240, plus all other sums, if any, that shall have become due and payable.  
Interest rate 5.69%    
Bank least   $ 10,000  
SVB [Member]      
Term debt     $ 8,000